Ipsen Deal Revamp Increases Independence for Inspiration
A new license, development and commercialization agreement between Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., and Paris-based Ispen SA will restructure the existing partnership between the firms and provide additional funding to Inspiration for development of hemophilia drugs IB1001 and OBI-1.
"Ipsen's been a good partner throughout these negotiations. We both have the same goal in mind, to help patients with hemophilia," Inspiration's chief commercial officer, Dan Regan, told BioWorld Today.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter